<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="372223">
  <stage>Registered</stage>
  <submitdate>25/01/2017</submitdate>
  <approvaldate>6/03/2017</approvaldate>
  <actrnumber>ACTRN12617000344392</actrnumber>
  <trial_identification>
    <studytitle>The Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Propolis and N-Acetylcysteine Compared to Placebo in Adults in Acute Condition with Sputum Production</studytitle>
    <scientifictitle>The Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Propolis and N-Acetylcysteine Compared to Placebo in Adults in Acute Condition with Sputum Production</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic obstructive pulmonary disease</healthcondition>
    <healthcondition>Acute and chronic bronchitis</healthcondition>
    <healthcondition>Asthma</healthcondition>
    <healthcondition>Chronic obstructive pulmonary disease</healthcondition>
    <healthcondition>Bronchitis</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The study assessing the efficacy and safety of a combination of propolis and N-Acetylcysteine (PropoMucil 600, Abela Pharm; 80mg propolis+600mg NAC) versus placebo in patients with asthma or COPD or bronchitis, with productive cough, one sachet of powder (3g), once daily for a period of 10 days (sachet will be prepared prior to administration, each sachet dissolved in 125ml (1/4 pint) of water.). A prospective, randomized, double-blind, placebo-controlled study will include 100 consecutive patients.
Empty, used, sachets must returned at the end of the treatment to the study site.</interventions>
    <comparator>1. PropoMucil 600 (80mg propolis + 600mg NAC), one sachet of powder (3g) orally, once daily for a period of 10 days.
2. Placebo (microcrystalline cellulose).</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
    <interventioncode>Rehabilitation</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Each patient will be assessed by expectorated amount of sputum (ml) by participant diary and collected by container for sputum</outcome>
      <timepoint>Baseline, and 10 days after end of therapy</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Determined the patients markers of inflammation (by measuring the C-reactive protein (CRP), fibrinogen and erythrocyte sedimentation rate (ESR)) from the blood samples (by serum assay), as composite primary outcome.</outcome>
      <timepoint>Baseline, and 10 days after end of therapy</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Patients` compliance using by participant diary</outcome>
      <timepoint>At end of 10 day treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cough effect on the quality of life through LEICESTER COUGH QUESTIONNAIRE-acute (LCQ-acute)</outcome>
      <timepoint>Baseline and 10 days after end of therapy</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety of product reported by questionnaire (fill it out for each of patient), special questionnaire created for the purpose of research</outcome>
      <timepoint>10 days after end of therapy</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Subjects are between the age of 18 and 85 with acute exacerbation of chronic obstructive pulmonary disease (COPD), acute and chronic bronchitis or asthma who have chest symptoms such as cough and sputum production (particularly increased breathlessness and cough, and increased sputum), treating with conventional therapy (corticosteroid and antibiotics)
2. Gender: both males and females
3. Informed, written consent will be obtained from all respondents (patients)
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. status asthmaticus
2. history of stomach or duodenal ulcer
3. &lt;18 years of age 
4. patients who are sensitive to NAC and propolis
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment> Allocation was concealed, by sealed opaque envelopes</concealment>
    <sequence>Subjects will be randomly allocated to the two study arms using simple randomisation procedures like coin-tossing. Groups will be matched by age, gender and diagnostic criteria.</sequence>
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>15/03/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>11/04/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>17/04/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Serbia and Montenegro</country>
      <state>Serbia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Abela Pharm</primarysponsorname>
    <primarysponsoraddress>Viline vode bb, 11000 Belgrade</primarysponsoraddress>
    <primarysponsorcountry>Serbia and Montenegro</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Abela Pharm</fundingname>
      <fundingaddress>Viline vode bb, 11000 Belgrade</fundingaddress>
      <fundingcountry>Serbia and Montenegro</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Municipal Institute for Lung Diseases and Tuberculosis</sponsorname>
      <sponsoraddress>Presevska 35, 11000 Belgrade</sponsoraddress>
      <sponsorcountry>Serbia and Montenegro</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Efficacy and safety of a combination of propolis and N-Acetylcysteine (NAC); (PropoMucil 600 manufactured by Abela Pharm, Serbia) versus placebo in patients with asthma or COPD, and productive cough for a period of 10 days as measured by the amount of sputum, cough impact on the patient, parameters of inflammation (C-reactive protein, erythrocyte sedimentation rate).</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics committee of Municipal Institute for Lung Diseases and Tuberculosis</ethicname>
      <ethicaddress>Presevska 35 
11000 Belgrade 
</ethicaddress>
      <ethicapprovaldate>17/10/2016</ethicapprovaldate>
      <hrec>5422/1</hrec>
      <ethicsubmitdate>10/10/2016</ethicsubmitdate>
      <ethiccountry>Serbia and Montenegro</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dejan Zujovic</name>
      <address>Municipal Institute for Lung Diseases and Tuberculosis
Presevska 35
 11000 Belgrade
Serbia</address>
      <phone>+38165 2230220</phone>
      <fax />
      <email>drzujovic@gmail.com</email>
      <country>Serbia and Montenegro</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Anita Agic</name>
      <address>Abela Pharm
Viline vode bb
11000 Belgrade
Serbia</address>
      <phone>+38163204797</phone>
      <fax />
      <email>anita.agic@proton.rs</email>
      <country>Serbia and Montenegro</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dejan Zujovic</name>
      <address>Municipal Institute for Lung Diseases and Tuberculosis
Presevska 35
 11000 Belgrade
Serbia</address>
      <phone>+38165 2230220</phone>
      <fax />
      <email>drzujovic@gmail.com</email>
      <country>Serbia and Montenegro</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>